# Palbociclib and Dexamethasone in Treating Participants With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia

> **NCT03472573** · PHASE1 · COMPLETED · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University** · enrollment: 7 (actual)

## Conditions studied

- Recurrent B Acute Lymphoblastic Leukemia
- Refractory B Acute Lymphoblastic Leukemia

## Interventions

- **DRUG:** Palbociclib
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT03472573
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-05-09
- **Primary completion:** 2021-08-04
- **Final completion:** 2022-06-09
- **Target enrollment:** 7 (ACTUAL)
- **Last updated:** 2025-05-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03472573

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03472573, "Palbociclib and Dexamethasone in Treating Participants With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT03472573. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*